In this issue:
HLA-C*06:02 and response to ustekinumab in plaque psoriasis
Continued secukinumab associated with high retention or regain of response
Online care vs in-person care for improving QoL in psoriasis
Secukinumab effects on cardiovascular disease parameters
Ustekinumab effects on systemic and vascular inflammation
All-cause and cause-specific mortality in psoriasis
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis
Long-term use of acitretin in psoriasis
Depression in psoriasis and risk of IHD/ cerebrovascular disease
Psychiatric disorders in paediatric patients with psoriasis
Mental health outcomes with biologic vs oral therapies
Please login below to download this issue (PDF)